FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $518.65M | ||||
Company | Location | Date | Amt. (M) | Details |
4-Antibody AG | Basel, Switzerland | 1/16/07 | CHF17 (US$13.6) |
4-Antibody raised CHF17M in its Series A round led by Advent Venture Partners; other investors were Biomedinvest AG, Grazia Equity GmbH, Life Sciences Partners and Mulligan Biocapital AG, as well as several private investors |
Althea Technologies Inc. |
San Diego | 1/9/07 | $23 | Investing in the Series C financing investment were funds managed by Telegraph Hill Partners |
Avesthagen Pvt. Ltd. |
Bangalore | 1/31/07** | €25 (US$32.3) | Investors in the round included Fidelity International, Limagrain Group, Daninvest and Bennett Coleman |
Ception Therapeutics Inc. |
Malvern, Pa. | 1/30/07 | $63 | Series C round was led by Essex Woodlands Health Ventures and included participation by Investor Growth Capital, MDS Life Sciences Technology Fund II, New Science Ventures and Aperture Venture Partners |
Conatus Pharmaceuticals Inc. |
San Diego | 1/3/07 | $5.5 | Conatus closed on the the first $5.5M in what was expected to be a $27.5M financing round; the round was led by Aberdare Ventures, and included Advent Venture Partners, Bay City Capital and Gilde Healthcare Partners |
Cylene Pharmaceuticals Inc. |
San Diego | 1/23/07 | $44 | Cylene raised $44M through a Series C round; investors were HBM BioVentures (Cayman) Ltd., Lilly Ventures, Sanderling Ventures, Novartis BioVenture Fund, BioVentures Investors, Research Corp. Technologies, Mitsui & Co. Venture Partners and Celgene Corp. |
Cytochroma Inc. |
Markham, Ontario | 1/17/07 | C$21 (US$17.9) | Cytochroma raised C$21M in a venture round led by VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund |
EyeGate Pharma Inc. |
Paris | 1/17/07 | $2 | Company raised $2M more, bringing the total raised in its Series B round to $12M; the first tranche was co-led by Innoven Partenaires and Ventech |
F-star | Vienna, Austria | 1/8/07 | €1.5 (US$1.95) | The seed financing was provided by Atlas Venture |
Horizon Therapeutics Inc.* |
Palo Alto, Calif. | 1/4/07 | $15 | Scale Venture Partners led the Series B round, which also included other Series A investors Sutter Hill Ventures and Pequot Ventures |
InteKrin Inc. | Palo Alto, Calif. | 1/11/07 | $23 | The Series A financing was led by Sofinnova Ventures and included OrbiMed Advisors and Vivo Ventures, as well as existing investors Asset Management and Sears Capital Management |
Juvaris BioTherapeutics Inc. |
Pleasanton, Calif. | 1/8/07 | $6 | The $6M was the first closing of what was expected to be a $12M Series A financing; it was provided by Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund |
NanoMed Pharmaceuticals Inc. |
Kalamazoo, Mich. | 1/31/07 | ND | Company completed the second close of its Series A round; the first close occurred in July 2006; SWMF Life Science Venture Fund was the primary investor |
Movetis NV | Vosselaar, Belgium | 1/8/07 | €49 (US$63.7) | The Series A financing round was led by Sofinnova Partners and Life Sciences Partners, and included Sofinnova Ventures, KBC, GIMV, Quest for Growth and BIP Investment Partners |
Novexel SA | Paris | 1/8/07 | €50 (US$65) | The Series B financing was led by Edmond de Rothschild Investment Parnters and included other new investors Goldman Sachs, Neomed and NIF SMBC, as well as existing investors Atlas Venture, Sofinnova, Abingworth, 3i, Novo A/S and BIT |
Osprey Pharmaceuticals Ltd. |
Montreal | 1/30/07 | $9 | The financing included $6M in tranched convertible debt from existing investors and $3M in venture debt from MMV Capital; the convertible debt placement was led by GeneChem Therapeutics Venture Fund and included Desjardins Capital Regional et Cooperatif, BDC Venture Capital and Western Technology Seed Investment Fund |
Phase Bioscience Inc. |
Durham, N.C. | 1/3/07 | ND | Johnson & Johnson Development Corp. provided the first tranche in the company's Series B financing |
Proprius Pharmaceuticals Inc. |
San Diego | 1/8/07 | $11 | The Series A financing was led by Atlas Venture, along with Forward Ventures and CDIB Bio- Science Venture Management, and included previous investors Fog City Fund and Windamere Venture Partners |
Semafore Pharmaceuticals Inc. |
Indianapolis | 1/5/07 | $9.5 | The Series B financing round included new and existing investors |
Sequoia Pharmaceuticals Inc. |
Gaithersburg, Md. | 1/8/07 | $35 | The Series C financing round was led by The Wellcome Trust and included other existing investors Healthcare Venture, Sofinnova Partners and Aberdare Ventures, and new investor MedImmune Ventures Inc. |
Symphogen AS | Copenhagen, Denmark | 1/31/07 | €5 (US$6.5) |
Symphogen added $6.5M to the latest round, bringing the total raised to $85M; the new funding came from Gilde Healthcare Partners |
Tigris Pharmaceuticals Inc. |
Bonita Springs, Fla. | 1/16/07 | $16 | Tirgris raised $16M in a Series B round led by NGN Capital LLC; other investors were Wexford Capital LLC and Bushido Capital Partners; Riverbank Capital Securities Inc. was placement agent |
Variation Biotechnologies Inc. |
Ottawa, Ontario | 1/4/07 | $35.7 | The Series A financing round was led by Clarus Ventures, and included ARCH Venture Partners, 5AM Ventures and existing seed investors |
Xcellerex Inc. | Marlborough, Mass. | 1/26/07 | $20 | The Series B round was led by SCG Group and Kleiner Perkins |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. |
To read more on related topics, click on one of the words below.